NOVAVAX INC

For the period ended Mar 31, 2024. Filed May 10, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 10, 2024

NVAX$10.20-6.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 1. Consolidated Financial Statements

Item 1. Financial Statements

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share information)

	For the Three Months EndedMarch 31,
	2024	2023
Revenue:
Product sales	$82,324	$(7,457)
Grants	—	87,379
Royalties and other	11,531	1,029
Total revenue	93,855	80,951
Expenses:
Cost of sales	59,209	34,086
Research and development	92,679	247,101
Selling, general, and administrative	86,798	112,532
Total expenses	238,686	393,719
Loss from operations	(144,831)	(312,768)
Other income (expense):
Interest expense	(4,111)	(4,316)
Other income	3,654	24,362
Loss before income taxes	(145,288)	(292,722)
Income tax expense	2,262	1,183
Net loss	$(147,550)	$(293,905)
Net loss per share:
Basic and diluted	$(1.05)	$(3.41)
Weighted average number of common shares outstanding:
Basic and diluted	139,916	86,158

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(in thousands)

	For the Three Months EndedMarch 31,
	2024	2023
Net loss	$(147,550)	$(293,905)
Other comprehensive loss:
Foreign currency translation adjustment	(13,547)	3,211
Other comprehensive income (loss)	(13,547)	3,211
Comprehensive loss	$(161,097)	$(290,694)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.